Uveal Melanoma Program
World Renowned Care
Takami Sato, MD, PhD
The renowned Uveal Melanoma Program at the Sidney Kimmel Cancer Center (SKCC) of Thomas Jefferson University, led by Takami Sato, MD, PhD, director, sees patients from across the country—and around the world. In addition to pioneering clinical care, researchers at SKCC are at the forefront of discovery to develop new treatments.
You can support the uveal melanoma program by making a gift today.
Create Your Own Fundraising Page
Creating a personal fundraising campaign of your own through Jefferson’s Uveal Melanoma Community Fundraising Program, or by contributing directly to other team pages listed here.
Host a Community Fundraising Event
Whether you’re putting on an athletic event or hosting an auction, Jefferson is here to help you raise money for the uveal melanoma program as successfully and easily as possible.
You Make the Difference
Your support will impact new clinical trials and life-impacting research.
This December, Marlana Orloff, MD, assistant professor of Medical Oncology at Thomas Jefferson University, will begin a two-year phase II trial study targeting uveal melanoma that has spread to the liver.
Another study, led by Andrew Aplin, PhD, associate director of Basic Research and program leader of Cancer Cell Biology and Signaling at SKCC, focuses on what causes some metastasized cancer cells to remain dormant and others to awaken, and whether it is possible to return growing uveal melanoma to a “sleeping” phase.
Other investigations include research into a uveal melanoma vaccine and direct infusion of natural killer (NK) cells into the hepatic artery to kill hepatic tumors—among others.
Our innovative researchers, including David J. Eschelman, MD, and Carin F. Gonsalves, MD, co-directors of the Division of Interventional Radiology, and Robert D. Adamo, MD, are making great progress in the laboratory—but there is much more work to do.
The next breakthrough, the next treatment—you make it possible. With a gift to Jefferson, you not only support our pathbreaking work—you can leave a legacy that will inspire future faculty and patients. You give people hope.
With the brightest minds, boldest ideas, and a reputation for nextgeneration and compassionate care, we are uniquely poised to make the most of your philanthropic investment, quickly transforming your generosity into tangible, life-saving medical successes.
An investment in this program is an investment in our patients. Thank you for helping them achieve the best possible quality of life.
Interested in learning more about SKCC’s research and recent media coverage of uveal melanoma? Click here.
Learn more about the Uveal Melanoma Program.
Uveal melanoma is the most common type of cancer in the adult eye, affecting two thousand Americans per year. It is also one of the most complex types of cancer—one that is largely unaffected by traditional treatments like chemotherapy.
Checks can be made payable to Jefferson and mailed to:
Office of Institutional Advancement
Attn: Uveal Melanoma Research Fund
125 South 9th Street, Suite 600
Philadelphia, PA 19107
If you have questions or would like to learn more, please contact Emma Laverty at Emma.Laverty@jefferson.edu or 215-503-8679.